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Abstract
Objective: To compare two definitions of neurocognitive impairment (NCI) in a large clinical trial of effectively-treated HIV-
infected adults at baseline.
Methods: Hopkins Verbal Learning test-Revised (HVLT-R), Colour Trail (CTT) and Grooved Pegboard (GPT) tests were applied
exploring five cognitive domains. Raw scores were transformed into Z-scores and NCI defined as summary NPZ-5 score one
standard deviation below the mean of the normative dataset (i.e. ,21SD) or Z-scores ,21SD in at least two individual
domains (categorical scale). Principal component analysis (PCA) was performed to explore the contribution of individual
tests to the total variance.
Results: Mean NPZ-5 score was 20.72 (SD 0.98) and 178/548 (32%) participants had NPZ-5 scores ,21SD. When
impairment was defined as ,21SD in at least two individual tests, 283 (52%) patients were impaired. Strong correlations
between the two components of the HVLT-R test (learning/recall) (r = 0.73), and the CTT and (attention/executive
functioning) (r = 0.66) were observed. PCA showed a clustering with three components accounting for 88% of the total
variance. When patients who scored ,21SD only in two correlated tests were considered as not impaired, prevalence of
NCI was 43%. When correlated test scores were averaged, 36% of participants had NPZ-3 scores ,21SD and 32%
underperformed in at least two individual tests.
Conclusion: Controlling for differential contribution of individual test-scores on the overall performance and the level of
correlation between components of the test battery used appear to be important when testing cognitive function. These
two factors are likely to affect both summary scores and categorical scales in defining cognitive impairment.
Trial registration: EUDRACT: 2007-006448-23 and ISRCTN04857074.
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Introduction
HIV-associated neurocognitive impairment (NCI) remains a
major issue in the care of chronic HIV management. Cognitive
impairment is still common, even among patients successfully
treated with anti-retroviral therapy (ART) [1,2]. However
controversy remains regarding the best way to, firstly, assess
cognitive function and secondly, interpret cognitive function
results in HIV-infected patients [3–5]. In research settings, a
typical approach is to take the average of demographically
adjusted scores on individual test domains to create a summary
score as a marker of cognitive function and in some cases, to use
this as markers to quantify cognitive impairment [2,6,7] but
summary scores assume equivalent contribution of each test score
on the overall summary score and do not offer differential
information on the cognitive domain which may be affected.
Other approaches such as the global deficit score have also been
used to generate overall composite scores but in general, these do
not offer differential information on the cognitive domain which
may be affected [8,9].
According to the 2007 revised research criteria for classifying
HIV-associated NCI (often known as the Frascati criteria or the
HIV-associated neurocognitive disorders (HAND) classification)
cognitive impairment is defined as performance of at least 1
standard deviation (SD) below the mean of demographically
adjusted normative datasets in at least two different cognitive
domains [10].
High level of agreement between summary deficit scores and
HAND classification results has been reported but the latter often
identified a larger number of impaired patients as compared to
summary score deficits [10,11]. This excess in diagnosis of
impairment usually correspond with mild forms of the condition
which may correspond to false positive results [3,5]. The aim of
this study was to compare these two methods to assess cognitive
function in a large population of effectively treated HIV-infected
adult individuals. In addition, we aimed to assess acceptability and
suitability of a screening test battery exploring five cognitive
domains in the context of a large randomised clinical trial (RCT).
Methods
Participant selection
This analysis used baseline data from individuals recruited into
a large treatment strategy trial for long-term management of
chronic HIV infection – the Protease Inhibitor monotherapy
Versus On-going Triple-therapy (PIVOT) trial. The trial enrolled
participants receiving a stable combination anti-retroviral therapy
(cART) regimen and a plasma HIV RNA ,50 copies/ml at
screening and for at least 24 weeks prior to study entry. 20% of the
study population had a history of an AIDS-defining condition.
Participants were recruited between November 2008 and July
2010 and followed-up until November 2013.
The PIVOT study is registered as EUDRACT: 2007-006448-
23 and ISRCTN04857074. National Research Ethics Service
(NRES) approval for the trial, including the NC assessments, was
obtained from the East of England Cambridge South Ethics
Committee. Written informed consent was obtained from all study
participants.
Neurocognitive testing
Neurocognitive testing was performed by designated research
staff at each study site after receiving appropriate training by the
coordinating centre. The training procedures included a face-to-
face session, a training video and practice of the tests with at least
five work colleagues before being allowed to assess study
participants, followed by yearly revision. Five cognitive domains
were explored with three different tests: Verbal learning and
memory were assessed using Hopkins Verbal Learning Test-
Revised (HVLT-R) [12], fine motor skills assessed using Grooved
Pegboard [13], and attention and executive function assessed using
Color Trails Tests (CTT) 1 and 2 respectively [14]. Neurocognitive
function was tested on all study participants at baseline and these
results have been reported elsewhere, but briefly 32% and 52% of
subjects showed summary deficit scores and HAND-like classifi-
cation results compatible with cognitive impairment when
standard normative data provided by the test manufacturers were
used [11].
Test performance was considered not valid if participants
decided to abandon the test before completion, in the case of
investigators failing to comply with standard procedures according
to the instructions or if the test was interrupted because of external
factors. In addition, all scores were centrally monitored and
extreme results were investigated and excluded if considered to be
related to any of the situations listed above.
Statistical analysis
Only participants with complete cognitive testing results
available were included in the analyses. Raw scores for each
cognitive test were transformed to z-scores using the manufactur-
ers’ normative data [12–14] adjusted for age (all tests) and years of
education (CTT) by subtracting the mean and dividing by the
standard deviation (SD) of test scores in reference populations. For
the Grooved Pegboard test the z-score was obtained by taking the
average of the z-scores for the dominant and non-dominant hands.
Summary z-scores (NPZ-5) were then calculated by averaging z-
scores of the 5 tests. For all individual test z scores and the NPZ-5,
scores below zero denote below-average neurocognitive function
compared to the reference population. Cognitive impairment was
defined using two approaches: a) a summary NPZ-5 one SD below
the mean of the normative dataset (i.e. , 21SD) (summary score)
and b) test scores ,21SD in at least two individual tests
(categorical scale).
Cochran’s Q test was used to ascertain heterogeneity of
impairment across the individual tests. To investigate the
relationship between all 5 tests, Pearson Correlation Coefficients
were calculated. Principal component analyses (PCA), using
correlation matrices, were performed to analyse the contribution
of individual test scores, or tests scores clustering together, on the
total variance of the 5 tests. First, a PCA without rotation and
keeping all components was applied to get an overall picture.
Principal components were orthogonal and uncorrelated. Second,
rotated PCA using the varimax method was performed to reduce
inter-component variance. Only those factors required to explain
at least 80% of the total variance were retained in the rotated
model which corresponded to 3 components based on the previous
correlation analyses. Here, factors have only low or high values to
facilitate interpretability of the components. Other rotation
methods were also applied as was PCA using raw test scores
instead of z-scores but results were very similar and therefore are
not shown.
Results
Patient characteristics and acceptability of cognitive
testing
Neurocognitive testing at baseline appeared to be highly
acceptable. Of the 587 participants recruited into PIVOT, only
one declined all tests. Overall, 548 (93%) participants produced
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valid results on all five tests and the proportion of missing, invalid
or discontinued tests was not exceeding 2% in any of the tests
except for the CTT-2 (4%). The demographic and clinical features
of the 39 patients who were unable to produce complete tests did
not differ from the general PIVOT population (Table 1).
Measurement of neurocognitive function
Mean NPZ-5 score was 20.72 (SD 0.98) and 178/548 (32%) of
the study participants had a NPZ-5 score ,21, compatible with
cognitive impairment. Mean Z-score for all tests were below the
normative average and ranged from 20.20 (SD 1.46) for the
CTT-2 to 21.36 (SD 1.96) for the GPT scores (Table 2); similarly
the proportion of participants having Z-scores ,21SD was lowest
for the CTT-2 test (22%) and highest (48%) for the GPT test (p,
0.001). When cognitive impairment was defined as,21 in at least
two individual tests (categorical scale) 283 (52%) patients were
impaired and of those patients 116 (21%), 84 (15%), 52 (9%), and
31 (6%) were ,21SD on 2, 3, 4, and all 5 tests, respectively
(Figure 1).
Overall agreement between the two definitions of impairment
was 79%, with 261 (48%) and 174 (32%) being classified as both
normal and both impaired, respectively. Of the remainder, 4
patients (0.7%) with NPZ-5 score ,21SD underperformed in
only one test/domain (the GPT test in all cases). The other 109
(20%) patients had Z-scores ,21SD on at least two cognitive
domains but had NPZ-5 scores within the normal range.
Correlation between individual test Z-scores
27% of patients had z-scores ,21 on both HVLT-R learning
and recall tests, 15% on HVLT-R learning but not recall test, and
8% on HVLT-R recall but not on learning test. 16% of patients
had z-scores ,21 on both CTT-1 and CTT-2, 18% on CTT-1
but not CTT-2, and 5% in CTT-2 but not on CTT-1. Table 3
shows the correlation matrix of the 5 individual neurocognitive
tests. There were strong correlations between a) HVLT-R learning
and HVLT-R recall tests (r = 0.73), and b) CTT-1 and CTT-2
(r = 0.66). GPT was more correlated with the two CTTs (r = 0.33
with each) than with the two HVLT-Rs (r = 0.17 and 0.15)
(Table 3).
Inter-test correlations were further analysed using PCA. The
first component explained 47% of the total variance and has
positive loadings of similar size on all variables, so could be
interpreted as overall neurocognitive functioning. The second
principal component explains 26% of the total variance and has
negative loadings of similar size on both parts of the HVLT-R and
positive loadings for the other tests, therefore differentiating
performance in HVLT-Rs versus CTT-1, CTT-2 and GPT. The
third principal component similarly differentiates performance in
both CTTs versus GPT and explains 15% of the total variance.
The fourth and fifth principal component only explain about 7%
and 5%, and differentiate performances in CTT-1 versus CTT-2,
and between the 2 parts of the HVLT-R, respectively. PCA with
rotation and restricted to 3 components showed a clustering
similar to the results of the correlation analyses: component 1
consisted of the two HVLT-R tests, component 2 of CTT-1 and 2,
and component 3 of the GPT (Table 4).
Based on this finding, we recalculated cognitive impairment
according to our categorical scale by reclassifying patients who
underperformed only on two strongly correlated tests (HVLT-R
both parts only (n = 36) or CTT-1 and 2 only (n = 14)) as ‘not
impaired’. Prevalence of cognitive impairment would then be 43%
rather than 52%. Similarly, when the two parts of the HVLT-R
and CTT are averaged first and then used to calculate a NPZ-3
score with the GPT 36% of study participants showed NPZ-3,21
whereas the proportion of participants with scores ,21 in two or
three tests was 32%.
Table 1. Baseline characteristics.
Gender, male 419 (76)
Age, years 44 (9)
Ethnicity
Caucasian 375 (68)
Black 153 (28)
Other 20 (4)
Nadir CD4+, cells/mL 177 (118)
Baseline CD4+, cells/mL 554 (217)
Years undetectable HIV RNA 4 (3)
Years education 15 (4)
Years on cART 5 (3)
Hepatitis C antibody positive 20 (4)
Baseline haemoglobin, g/dL 14 (1)
Data are number (%) or mean (standard deviation).
doi:10.1371/journal.pone.0103498.t001
Table 2. Description of neurocognitive tests.
Test Cognitive domain Raw test value
¥ z-score impaired
(median, IQR) (mean, sd) (median, IQR) (z-score ,21)
HVLT-R learning Verbal learning 25 (22, 29) 20.70 (1.16) 20.69 (21.48, 0.12) 229 (42%)
HVLT-R recall Verbal memory 9 (7, 11) 20.58 (1.17) 20.45 (21.49, 0.38) 193 (35%)
Color Trail Test 1 Attention/speed of information processing 0:43 (0:34, 0:56) 20.74 (1.38) 20.46 (21.43, 0.27) 188 (34%)
Color Trail Test 2 Executive functioning 1:21 (1:05, 1:42) 20.20 (1.46) 0.11 (20.87, 0.80) 118 (22%)
Grooved Pegboard Testp Fine motor skills/complex perceptual 1:17 (1:09, 1:27) 21.36 (1.96) 20.96 (22.07, 20.17) 264 (48%)
NPZ-5
$ Global z-score - 20.72 (0.98) 20.52 (21.23, 20.05) 178 (32%)
Notes: HVLT-R: Hopkins Verbal Learning Test–Revised; paverage of left and right hand;
$
Average of the 5 tests; ¥HVLT: words remembered correctly, other tests: min:s.
N = 548.
doi:10.1371/journal.pone.0103498.t002
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Discussion
NCI is an important morbidity in HIV-infected populations and
the Frascati criteria is the most widely used and accepted method
of diagnosis and classification. However there are concerns about
some possible limitations of this approach, particularly in the case
of asymptomatic or milder forms of the condition [3–5]. In this
group of virologically suppressed patients on cART we performed
standard neurocognitive tests and explored the effect of using
different approaches to analysis and classification of impairment.
These approaches yielded differing results. When using summary
NPZ-5 scores, calculated by averaging Z-scores for all explored
cognitive domains, the proportion of cognitively impaired patients
was 32%, whereas using a categorical scale (defined by poor
performance on at least two domains) it was 52%.
Summary scores have frequently been used to assess cognitive
function in HIV-infected patients [15–17] and other medical
conditions [18]. They provide single numerical results, particularly
useful for monitoring change in cognition over time and have been
utilised in the context of an RCT exploring interventions to treat
HIV-associated NCI [19]. However, with a summary score such as
NPZ-5, all individual test scores contribute equally, which may not
reflect their individual relationship to overall neurocognitive
dysfunction. In our study, neurocognitive testing generated data
where some variables were highly correlated which may suggest
that a simple average of individual tests Z-scores may not be an
optimal method to identify cognitive impairment. Normalising
scores by transforming them into Z-scores adds another limitation,
as available manufacturers’ normative data (obtained with
populations of unknown HIV status) may not be entirely
appropriate for comparison with HIV-infected populations
[11,20]. Other methods also based on average scores that are
used to measure cognitive function by normalising raw-scores,
such as the global deficit score (GDS) and the clinical rating system
(CR), may not be affected by the limitations generated by the lack
of suitable normative population datasets, but these do not take
into consideration the level of correlation between functional
domain scores. When compared head to head, GDS and CR also
Figure 1. Proportion of patients with functional domains impaired (,21SD), overall and by number of tests impaired.
doi:10.1371/journal.pone.0103498.g001
Table 3. Correlation matrix of neurocognitive tests.
HVLT-R learning HVLT-R recall CTT 1 CTT 2 GPT
HVLT-R learning 1
HVLT-R recall 0.73 1
CTT 1 0.23 0.19 1
CTT 2 0.26 0.24 0.66 1
GPT 0.17 0.15 0.33 0.33 1
Notes: correlation coefficients using test z-scores; HVLT-R: Hopkins Verbal Learning Test–Revised; CTT: Color Trail Test; GPT: Grooved Pegboard Test (average of left and
right hand). Pearson Correlation Coefficient; p-value ,0.001 for all correlations.
doi:10.1371/journal.pone.0103498.t003
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generated differing results with the CR system classifying as
impaired a larger proportion of patients than GDS [8].
By using 1 SD below the normative mean to define impairment,
and assuming normal distribution of the data, 16% of individuals
with normal cognitive function are expected to be classified as
impaired for a single test. In categorical evaluation systems such as
the Frascati criteria the probability of underperforming in two or
more cognitive domains will depend on the number of tests
performed (the higher the number of tests, the higher the
probability of obtaining two or more abnormal results) and the
level of correlation between them (there would be a high
probability of failing two or more highly correlated tests or
domains) and therefore, the false positive rate increases with
multiple testing and multiple measures in a complex fashion
[3,21]. Using a more strict cut-off (e.g. ,21.5 or 2 SD) to define
impairment (and perhaps limiting the number of measures
included on the testing battery to explore performance on key
cognitive domains, to those with low inter-correlation) may
provide a more accurate approach to identify cognitive impair-
ment. However, using a stricter cut-off may decrease the sensitivity
of the testing battery, thus increasing the rate of false negatives.
We chose a cut-off of 21SD for the summary score to define
impairment, however, it should be noted that the standard
deviation of an average is smaller than single test scores (again
depending on the correlation between individual tests) and,
therefore, also the proportion below 21SD in a summary score
compared with a single test.
PCA is a useful tool to reduce a large set of correlated scores
into clusters of independent factors which could help in better
understanding their contribution in the overall variance of the
different scores. PCA generates weighted average scores which
could be used summarise performance on cognitive testing
batteries. Although the PIVOT battery was brief and involved
only one test for each of the five cognitive domains explored, PCA
showed scores clustering in an expected fashion in three
independent factors which explained 88% of the overall variance.
If patients in whom test scores were ,21 only in two domains
clustering together in a single PCA factor were reclassified as ‘not
impaired’, 43% of our study population could be considered as
cognitively impaired, a prevalence lower than previously reported
[22,23]. The first component from our PCA un-rotated model
showed similar loadings on all tests suggesting similar contribution
on the overall variance (Table 4) and therefore, may support the
appropriateness of using a simple average of test scores to
summarise cognitive function. However, the GPT showed a
somewhat smaller contribution reflecting its lower correlation with
the other tests, and it could be suspected that the cognitive domain
it measures has less weight in a simple average. As an alternative
approach to measure cognitive function we averaged the two
parts of the HVLT-R and CTT to calculate an NPZ-3 score.
Here, we observed a greater level of agreement between the two
definition of NCI as 36% and 32% of study participants showed
NPZ-3 ,21 and scores ,21 in two or three tests, respectively.
Our study population was large, homogenous, effectively
treated and derived from a multi-centre study which confers some
strength to our findings. However, our testing battery was brief
and by no means comprehensive. Using a larger battery may
generate different prevalence of NCI even in the same population,
perhaps increasing sensitivity. However, depending of the level of
correlation between tests, including a larger number of observa-
tions may increase the probability of $2 abnormal results [3].
Simioni et al reported a very high prevalence (84%) of NCI in
effectively suppressed patients using a very large battery and
adjusting their analysis for multiple comparisons but not for
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correlation between the 39 scores used [22]. On the other hand, a
number of short (2–4 tests) batteries exploring each cognitive
domain with a single test have demonstrated good sensitivity
(60–87%) and specificity (83–91%) compared to a comprehensive
test battery [24].
Prevalence of NCI is highly dependent not only on the
definition used, but also on normative datasets utilised for analysis
since a number of socio-demographic and cultural factors might
impact performance on neuropsychological tests. In our original
analysis we used normative data provided by the manufacturers of
each test as well as ethnicity-adjusted sets for the CTT and the
HVLT-R to calculate prevalence of NCI [11,25]. Large cross-
sectional studies have used additional normative datasets corrected
by factors such as education, gender and age to calculate NCI
have reported prevalences ranging between 52–58%, similar to the
prevalence reported by us when the manufactures’ dataset was
used (52%) [26,27]. Because the main aim of this analysis was
explore the discordance between the calculated prevalence of NCI
with two different definitions of impairment, we decided to use the
same normative datasets used for our initial analysis [11].
Exploring the PIVOT battery and clustering of test scores using
PCA in a cohort of HIV-negative individuals would generate some
valuable data.
In summary, our analysis showed discrepancies between the two
definitions of NCI with the categorical scale being more likely to
identify a larger proportion of study participants as impaired
compared to the summary score. Taking into consideration
correlations between individual test scores and adjusting test scores
with methods such as PCA may have greater overall neuropsy-
chological validity.
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